OBJECTIVES: The objective of this study was to carry out an economic evaluation of a combination of tiotropium/olodaterol administrated through the Respimat inhaler as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD) from both the public payer’s (National Health Fund-NHF) and common (patients and NHF) perspectives in Poland. METHODS: Five comparators were included: tiotropium/olodaterol was compared with tiotropium and fluticasone/salmeterol combination therapy in a cost-utility analysis and with three LAMA+LABA combination therapies (tiotropium+formoterol, tiotropium+indacaterol, tiotropium+salmeterol) a cost-minimization analysis as they have similar efficacy and comparable safety profile to tiotropium/olodaterol. A patient level Markov model with life-time horizon included four health states defined by GOLD stages and death. Drug cost, disease management, cost of rescue medication and exacerbations were estimated in 2015. Clinical data were obtained from the performed network meta-analyses. RESULTS: Quality adjusted life years related with tiotropium/olodaterol and tiotropium generated 8.150 QALY and 7.977 QALY, respectively. The difference is caused by alternative sources of clinical data. The incremental cost-utility ratio (ICUR) of tiotropium/olodaterol vs tiotropium was estimated to be €8,828/QALY from NHF and €11,982/QALY from common perspective. QALY associated with tiotropium/olodaterol arm and fluticasone/salmeterol arm resulted in 8.091 QALY and 7.818 QALY, respectively. The ICUR of tiotropium/olodaterol vs fluticasone/salmeterol amounted to be €5,165/QALY from NHF and €10,029/QALY from common perspective. The results of CUA were below the threshold accepted for Poland (€28,586/QALY). The incremental cost for the comparisons of tiotropium/olodaterol vs: tiotropium+formoterol, tiotropium+indacaterol and tiotropium+salmeterol was estimated to be -€592, -€216, -€592, respectively from NHF perspective and €583, ‑€841, €534, respectively from common perspective. CONCLUSIONS: Use of tiotropium/olodaterol in a maintenance treatment of patients with COPD is a cost-effective strategy in comparison to tiotropium and fluticasone/salmeterol. Furthermore the assessed technology is less expensive than LAMA+LABA combination therapies from NHF perspective.